ImmunityBio, Inc. (IBRX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
ImmunityBio, Inc.
Address
3530 John Hopkins Court
San Diego, CA 92121
United States of America (the)
Phone
858 633 0300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
688
First IPO Date
July 28, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Richard Gerald Adcock | President, Chief Executive Officer & Director | 1.58M | 1969 |
| Regan J. Lauer | Chief Accounting Officer | 522,490 | 1970 |
| David C. Sachs | Chief Financial Officer | 902,174 | 1978 |
| Patrick Soon-Shiong FRCS | Founder, Executive Chairman and Global Chief Scientific & Medical Officer | 1.15M | 1953 |
| Hans Georg Klingemann | Chief Science Officer of Cellular | 0 | 1950 |
| Enrique Diloné | Chief Technology Officer | 0 | 1967 |
| Leonard S. Sender | Chief Medical Officer of Liquid Tumors & Cell Therapy | 0 | N/A |
| Sandeep K. Reddy | Chief Medical Officer | 0 | N/A |
| Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | 0 | N/A |
| Barry J. Simon | Chief Corporation Affairs Officer & Director | 0 | 1965 |
| Emily Arison | Senior Vice President of Human Resources | 0 | N/A |
Description
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
